ArticleCancers2023

The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer.

Michele Vigolo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.